OMMA recently sent notices regarding safety concerns with products tested by Greenleaf Labs for total yeast and mold between 2023 and 2025. This message serves as a follow-up to the agency's previous communication.
Greenleaf is actively working with its customers to conduct and pay for retesting, ensuring unsafe products are not sold to patients. Products that pass retesting meet safety standards and are compliant with OMMA Rules. Products that fail retesting can be remediated (processing failed marijuana into a solvent-based concentrate) or decontaminated (treatment to remove or reduce contaminants that exceed allowable limits). Whether products are remediated or decontaminated, they must pass required testing. Products that fail retesting and are not remediated or decontaminated by licensees are not safe for consumption. Products in "test failed" status do not meet safety standards and cannot legally be sold by dispensaries to patients. Products must be in "test passed" or "retest passed" status to be sold to patients.
All products must undergo retesting before a recall can be completed. When all necessary steps have been taken, patients can verify the safety of their products by checking their packaging/product label for the batch number and comparing it to a product table listed on OMMA's website.
